杜氏肌营养不良症的DMD基因型与运动功能:一项多机构荟萃分析及其对临床试验的启示
本研究基于6个真实世界/自然史数据源、超过700例患者、逾1600患者年的随访,量化了DMD基因型类别对1年运动功能终点变化的影响。研究发现所研究的基因型类别仅解释约2%的ΔNSAA变异,而其他预后因素解释超过30%,校正非基因型预后因素后各跳跃适用突变类别的合并效应估计均较小(ΔNSAA总分1年随访<2分),标准误<1分。作者认为这些发现提示纳入基因型混合或不匹配对照、为期至多12个月的试验设计在运动功能结局方面具有可行性。
要点
- 所研究的基因型类别仅解释约2%的12个月ΔNSAA变异,其他预后因素解释超过30%。
- 校正非基因型预后因素后,各跳跃适用突变类别的合并效应估计均较小(ΔNSAA总分1年随访<2分)。
- 作者认为这些发现提示纳入基因型混合或不匹配对照、为期至多12个月的试验设计具有可行性。
核心结论
- 所研究的基因型类别对1年运动功能终点变化的效应较小,作者认为这提示纳入基因型混合或不匹配对照、为期至多12个月的试验设计具有可行性。
研究设计与样本
- 多机构荟萃分析,基于6个真实世界/自然史数据源(UZ Leuven、PRO-DMD-01 shared by CureDuchenne、iMDEX、North Star UK、Cincinnati Children's Hospital Medical Center和DMD Italian Group),超过700例患者、逾1600患者年随访。
- 基因型分类为适合跳跃外显子44、45、51或53,或其他可跳跃、无义突变及其他突变。
- 在各数据源中研究基因型类别与1年North Star Ambulatory Assessment总分变化(ΔNSAA)及10米步行/跑速度变化(Δ10MWR)的关联,并分别在有和无基线预后因素校正下分析。
主要发现
- 所研究的基因型类别在12个月后解释约2%的ΔNSAA结局变异,而其他预后因素在大型数据源中解释超过30%的变异。
- 基于所有数据源的荟萃分析,所研究的跳跃适用突变类别的合并效应估计均较小(1年随访中ΔNSAA总分<2分),小于NSAA的临床重要差异,且校正非基因型预后因素后标准误<1分,估计精确。
临床怎么用
- 作者认为这些发现提示纳入基因型混合或不匹配对照、为期至多12个月的试验设计在运动功能结局方面具有可行性,可缓解招募困难并减少分配至安慰剂的患者数量。
- 作者建议此类试验设计(包括多基因型平台试验和混合设计)应确保治疗组和对照组之间最重要的预后因素基线平衡,同时考虑本研究所量化的少量剩余基因型效应。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Clinical trials of genotype-targeted treatments in Duchenne muscular dystrophy (DMD) traditionally compare treated patients with untreated patients with the same DMD genotype class. This avoids confounding of drug efficacy by genotype effects but also shrinks the pool of eligible controls, increasing challenges for trial enrollment in this already rare disease. To evaluate the suitability of genotypically unmatched controls in DMD, we quantified effects of genotype class on 1-year changes in motor function endpoints used in clinical trials. METHODS: More than 1,600 patient-years of follow-up (>700 patients) were studied from 6 real-world/natural history data sources (UZ Leuven, PRO-DMD-01 shared by CureDuchenne, iMDEX, North Star UK, Cincinnati Children's Hospital Medical Center, and the DMD Italian Group), with genotypes classified as amenable to skipping exons 44, 45, 51, or 53, or other skippable, nonsense, and other mutations. Associations between genotype class and 1-year changes in North Star Ambulatory Assessment total score (ΔNSAA) and in 10-m walk/run velocity (Δ10MWR) were studied in each data source with and without adjustment for baseline prognostic factors. RESULTS: The studied genotype classes accounted for approximately 2% of variation in ΔNSAA outcomes after 12 months, whereas other prognostic factors explained >30% of variation in large data sources. Based on a meta-analysis across all data sources, pooled effect estimates for the studied skip-amenable mutation classes were all small in magnitude (<2 units in ΔNSAA total score in 1-year follow up), smaller than clinically important differences in NSAA, and were precisely estimated with standard errors <1 unit after adjusting for nongenotypic prognostic factors. DISCUSSION: These findings suggest the viability of trial designs incorporating genotypically mixed or unmatched controls for up to 12 months in duration for motor function outcomes, which would ease recruitment challenges and reduce numbers of patients assigned to placebos. Such trial designs, including multigenotype platform trials and hybrid designs, should ensure baseline balance between treatment and control groups for the most important prognostic factors, while accounting for small remaining genotype effects quantified in this study.
引用
- Muntoni F, Signorovitch J, Sajeev G, et al. DMD Genotypes and Motor Function in Duchenne Muscular Dystrophy: A Multi-institution Meta-analysis With Implications for Clinical Trials. Neurology. 2023. PMID: 36725339. doi:10.1212/WNL.0000000000201626
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。